Cargando…

Efficacy and safety of ustekinumab in adolescents

The biologic agent ustekinumab is a human monoclonal antibody that binds to the p40 subunit shared by interleukins (ILs) 12 and 23. The antibody is able to prevent binding of cytokines to the IL-12Rβ1 cell surface receptor and therefore may prevent IL-23 driven activation of the IL-23/Th 17 axis of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kellen, Roselyn, Silverberg, Nanette B, Lebwohl, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683279/ https://www.ncbi.nlm.nih.gov/pubmed/29388600 http://dx.doi.org/10.2147/PHMT.S75836

Ejemplares similares

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
por: Sandborn, W. J., et al.
Publicado: (2018)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

Pediatric psoriasis: an update
por: Silverberg, Nanette B
Publicado: (2009)

Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)

Ustekinumab for the treatment of psoriatic arthritis: an update
por: Davari, Parastoo, et al.
Publicado: (2014)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment
por: Yu, Qianying, et al.
Publicado: (2022)

The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
por: Chiu, Hsien-Yi, et al.
Publicado: (2015)

Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement
por: Toussirot, Éric, et al.
Publicado: (2013)

Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
por: Abreu, Maria T, et al.
Publicado: (2022)

Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index
por: Walshe, Margaret, et al.
Publicado: (2021)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis
por: Krulig, Eliana, et al.
Publicado: (2010)

Severe Refractory Atopic Dermatitis in an Adolescent Patient Successfully Treated with Ustekinumab
por: Agusti-Mejias, Anna, et al.
Publicado: (2013)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
por: Bagel, Jerry, et al.
Publicado: (2018)

Potential role of ustekinumab in the treatment of chronic plaque psoriasis
por: Mercuri, Santo Raffaele, et al.
Publicado: (2010)

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
por: Papoutsaki, Marina, et al.
Publicado: (2009)

Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review
por: Merola, Joseph F., et al.
Publicado: (2022)

Long-term effectiveness and safety of ustekinumab in Crohn’s disease: a prospective cohort study
por: Thomas, Pepijn W.A., et al.
Publicado: (2022)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

Late Reaction to Ustekinumab Infusion
por: Morais, Marina Resener, et al.
Publicado: (2013)

Ustekinumab-associated disseminated verrucae
por: Anderson, Mary E., et al.
Publicado: (2018)

Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
por: Mahé, E., et al.
Publicado: (2022)

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus
por: van Vollenhoven, Ronald F, et al.
Publicado: (2022)

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
por: Asahina, Akihiko, et al.
Publicado: (2023)

Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
por: Montepaone, Monica, et al.
Publicado: (2014)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
por: Matsumoto, Satohiro, et al.
Publicado: (2018)

Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
por: Heron, Valerie, et al.
Publicado: (2022)

Morphea in a patient undergoing treatment with ustekinumab
por: Steuer, Alexa B., et al.
Publicado: (2019)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease
por: Hermanns-Lê, Trinh, et al.
Publicado: (2012)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
por: Deepak, Parakkal, et al.
Publicado: (2016)

Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease
por: Tuskey, Anne, et al.
Publicado: (2014)

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab
por: Pugliese, Daniela, et al.
Publicado: (2022)

Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan
por: Yokoyama, Seiji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lfkirdq6obm9o35neekhqa0vnr